Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

International Journal of Hematology
Hideho HenzanFukuoka Blood & Marrow Transplantation Group (FBMTG)

Abstract

We stratified patients with newly diagnosed acute promyelocytic leukemia (APL) according to a white blood cell (WBC) count of ≥ 3 × 109/L (high risk) or < 3 × 109/L (low risk) before administering risk-adapted chemotherapy in combination with all-trans retinoic acid (ATRA). In total, 27 low-risk and 23 high-risk patients were assigned to receive induction and three courses of consolidation with ATRA and anthracycline, followed by 2-year maintenance regimen. High-risk group additionally received cytarabine during 1st consolidation and another one-shot idarubicin treatment during 3rd consolidation. We prospectively monitored measurable residual disease (MRD) after induction and each consolidation. In the low-risk and high-risk groups, 5-year disease-free survival (DFS) rates were 86.5% and 81.2% (p = 0.862), and 5-year overall survival rates were 100% and 84.8% (p = 0.062), respectively. In the MRD-negative and MRD-positive groups, 5-year DFS rates were 91.7% and 78.4% (p = 0.402) and 84.7% and 60.0% (p = 0.102) after induction and 1st consolidation, respectively. Relapse rates were 8.3% and 13.3% (p = 0.570) and 9.0% and 40.0% (p = 0.076) after induction and 1st consolidation, respectively. Achieving MRD-negativity after 1st con...Continue Reading

References

Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lionel AdèsUNKNOWN European Acute Promyelocytic Leukemia Group
May 6, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charikleia KelaidiLionel Adès
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David GrimwadeAlan K Burnett
Mar 10, 2011·Blood·Giuseppe AvvisatiUNKNOWN GIMEMA, AIEOP, and EORTC Cooperative Groups
Jul 28, 2011·Cancer Science·Tomohiko KamimuraKoichi Akashi
Mar 24, 2012·Blood·Nicola GökbugetUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Jul 12, 2013·The New England Journal of Medicine·Francesco Lo-CocoUNKNOWN Study Alliance Leukemia
Jun 19, 2014·International Journal of Hematology·Junmin LiZhenyi Wang
Sep 24, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katsuji ShinagawaTomoki Naoe
Sep 19, 2015·The Lancet Oncology·Alan K BurnettUNKNOWN UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group
Jan 1, 2015·Rare Cancers and Therapy·Federico De Angelis, Massimo Breccia
Dec 4, 2016·Hematology·Sameem Abedin, Jessica K Altman
Sep 1, 2017·International Journal of Hematology·Norio AsouKatsuji Shinagawa
May 31, 2018·International Journal of Hematology·Kazuyuki SatoIkuo Miura
Jul 22, 2018·Leukemia·Laura CicconiFrancesco Lo-Coco
Oct 20, 2018·Nature·Jeffrey W TynerBrian J Druker

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.